Ignite Creation Date:
2024-05-06 @ 8:22 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06351020
Status:
RECRUITING
Last Update Posted:
2024-07-01
First Post:
2024-03-15
Brief Title:
LM-302 for the Treatment of Subjects With Claudin182-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
Sponsor:
LaNova Medicines Zhejiang Co Ltd
Organization:
LaNova Medicines Limited
Study Overview
Official Title:
A Phase III Open-Label Multi Center Randomized Study of LM-302 Versus Treatment of Physicians Choice TPC in Patients With CLDN182-Positive Locally Advanced or Metastatic GastricGC and Gastroesophageal JunctionGEJ Adenocarcinoma
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will assess the efficacy and safety of LM-302 Versus Treatment of Physicians Choice TPC in Subjects With locally advanced or metastatic Claudin CLDN 182-positive Gastric or Gastroesophageal Junction Adenocarcinoma who have progressed on or after 2 lines of systemic therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None